Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2022-05-12 Purchase |
2022-05-13 4:37 pm |
Verve Therapeutics Inc. | VERV | ADELMAN BURT A Director |
10,000 | $12.15 | $121,526 | 428,326 (Indirect) |
View |
| 2022-03-15 Purchase |
2022-03-17 07:58 am |
Verve Therapeutics Inc. | VERV | ADELMAN BURT A Director |
4,000 | $21.38 | $85,535 | 418,326 (Indirect) |
View |
| 2022-03-09 Sale |
2022-03-11 5:59 pm |
Verve Therapeutics Inc. | VERV | FMR LLC See Remark 1 10% Owner |
3,971 | $29.01 | $115,199 | 825,723 (Indirect) |
View |
| 2022-02-09 Sale |
2022-02-11 10:40 am |
Verve Therapeutics Inc. | VERV | FMR LLC See Remark 1 10% Owner |
13,190 | $29.46 | $388,577 | 829,694 (Indirect) |
View |
| 2022-02-01 Sale |
2022-02-03 11:43 am |
Verve Therapeutics Inc. | VERV | FMR LLC See Remark 1 10% Owner |
35,574 | $29.04 | $1,033,069 | 842,884 (Indirect) |
View |
| 2022-01-26 Sale |
2022-01-28 5:04 pm |
Verve Therapeutics Inc. | VERV | FMR LLC See Remark 1 10% Owner |
158,836 | $31.12 | $4,943,419 | 878,458 (Indirect) |
View |
| 2022-01-04 Sale |
2022-01-06 4:36 pm |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
1,870 | $39.9 | $74,613 | 835,955 (Indirect Direct) |
View |
| 2021-12-27 Sale |
2021-12-29 4:38 pm |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
48,693 | $40.16 | $1,955,534 | 1,113,813 (Indirect Direct) |
View |
| 2021-12-22 Sale |
2021-12-27 6:12 pm |
Verve Therapeutics Inc. | VERV | Bellinger Andrew Chief Scientific Officer |
15,000 | $38.7 | $580,469 | 151,995 (Direct) |
View |
| 2021-12-22 Sale |
2021-12-27 6:08 pm |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
114,000 | $39.3 | $4,480,604 | 1,261,506 (Indirect Direct) |
View |
| 2021-12-02 Purchase |
2021-12-06 08:12 am |
Verve Therapeutics Inc. | VERV | Ashe Andrew D. See Remarks |
4,000 | $32.1 | $128,420 | 170,722 (Direct) |
View |
| 2021-12-02 Purchase |
2021-12-06 08:11 am |
Verve Therapeutics Inc. | VERV | ADELMAN BURT A Director |
4,700 | $31.34 | $147,304 | 414,326 (Indirect) |
View |
| 2021-06-21 Purchase |
2021-06-23 4:16 pm |
Verve Therapeutics Inc. | VERV | Redmile Group LLC Green Jeremy 10% Owner |
1,050,000 | $19 | $19,950,000 | 1,936,530 (Indirect) |
View |
| 2021-06-21 Purchase |
2021-06-23 4:02 pm |
Verve Therapeutics Inc. | VERV | Cormorant Asset Management LP Chen Bihua Cormorant Global Healthcare Master Fund LP Cormorant Private Healthcare Fund III LP Former 10% Owner |
275,000 | $19 | $5,225,000 | 984,224 (Indirect) |
View |
| 2021-06-21 Purchase |
2021-06-22 5:21 pm |
Verve Therapeutics Inc. | VERV | Logos Global Management LP 10% Owner |
370,000 | $19 | $7,030,000 | 813,265 (Indirect Direct) |
View |
| 2021-06-21 Purchase |
2021-06-22 5:20 pm |
Verve Therapeutics Inc. | VERV | Rock Springs Capital Management LP Rock Springs Capital Master Fund LP Rock Springs Capital LLC 10% Owner |
370,000 | $19 | $7,030,000 | 152,926 (Indirect) |
View |
| 2021-06-21 Purchase |
2021-06-22 5:17 pm |
Verve Therapeutics Inc. | VERV | Novo Holdings A/S 10% Owner |
350,000 | $19 | $6,650,000 | 793,265 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2022-06-09 Option Award |
2022-06-13 5:00 pm |
N/A 2032-06-08 |
Verve Therapeutics Inc. | VERV | ADELMAN BURT A Director |
15,500 | $0 | 15,500 (Direct) |
View |
| 2022-06-09 Option Award |
2022-06-13 5:00 pm |
N/A 2032-06-08 |
Verve Therapeutics Inc. | VERV | Mikhail Sheila Director |
15,500 | $0 | 15,500 (Direct) |
View |
| 2022-06-09 Option Award |
2022-06-13 5:00 pm |
N/A 2032-06-08 |
Verve Therapeutics Inc. | VERV | MacLean Michael F Director |
15,500 | $0 | 15,500 (Direct) |
View |
| 2022-06-09 Option Award |
2022-06-13 5:00 pm |
N/A 2032-06-08 |
Verve Therapeutics Inc. | VERV | Evans John M. Director |
15,500 | $0 | 15,500 (Direct) |
View |
| 2022-03-18 Exercise |
2022-03-22 07:41 am |
N/A 2030-09-15 |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
69,674 | $0 | 1,244,827 (Direct) |
View |
| 2022-03-18 Exercise |
2022-03-22 07:41 am |
N/A N/A |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
69,674 | $2.87 | 1,244,827 (Direct) |
View |
| 2022-02-11 Option Award |
2022-02-15 09:00 am |
N/A 2032-02-10 |
Verve Therapeutics Inc. | VERV | Dorval Allison Chief Financial Officer |
60,000 | $0 | 60,000 (Direct) |
View |
| 2022-02-11 Option Award |
2022-02-15 08:58 am |
N/A 2032-02-10 |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
332,000 | $0 | 332,000 (Direct) |
View |
| 2022-02-11 Option Award |
2022-02-15 08:57 am |
N/A 2032-02-10 |
Verve Therapeutics Inc. | VERV | Bellinger Andrew Chief Scientific Officer |
125,000 | $0 | 125,000 (Direct) |
View |
| 2022-02-11 Option Award |
2022-02-15 08:56 am |
N/A 2032-02-10 |
Verve Therapeutics Inc. | VERV | Ashe Andrew D. See Remarks |
125,000 | $0 | 125,000 (Direct) |
View |
| 2022-01-04 Exercise |
2022-01-06 4:36 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
1,870 | $1.39 | 835,955 (Direct) |
View |
| 2022-01-04 Exercise |
2022-01-06 4:36 pm |
N/A 2029-04-14 |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
1,870 | $0 | 835,955 (Direct) |
View |
| 2021-12-27 Exercise |
2021-12-29 4:38 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
48,693 | $1.39 | 1,113,813 (Direct) |
View |
| 2021-12-27 Exercise |
2021-12-29 4:38 pm |
N/A 2029-04-14 |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
48,693 | $0 | 1,113,813 (Direct) |
View |
Ownership |
2021-12-28 12:16 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | FMR LLC See Remark 1 10% Owner |
0 | $0 | 1,037,294 (Indirect) |
View |
| 2021-12-22 Exercise |
2021-12-27 6:12 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Bellinger Andrew Chief Scientific Officer |
15,000 | $1.48 | 151,995 (Direct) |
View |
| 2021-12-22 Exercise |
2021-12-27 6:12 pm |
N/A 2029-09-16 |
Verve Therapeutics Inc. | VERV | Bellinger Andrew Chief Scientific Officer |
15,000 | $0 | 151,995 (Direct) |
View |
| 2021-12-22 Exercise |
2021-12-27 6:08 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
114,000 | $1.39 | 1,261,506 (Direct) |
View |
| 2021-12-22 Exercise |
2021-12-27 6:08 pm |
N/A 2029-04-14 |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
114,000 | $0 | 1,261,506 (Direct) |
View |
| 2021-12-16 Option Award |
2021-12-17 4:41 pm |
N/A 2031-12-15 |
Verve Therapeutics Inc. | VERV | Bellinger Andrew Chief Scientific Officer |
55,000 | $0 | 55,000 (Direct) |
View |
| 2021-11-29 Option Award |
2021-11-30 4:26 pm |
N/A 2031-11-28 |
Verve Therapeutics Inc. | VERV | Dorval Allison Chief Financial Officer |
142,500 | $0 | 142,500 (Direct) |
View |
| 2021-06-21 Other |
2021-06-23 6:13 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Broad Institute Inc. 10% Owner |
387,830 | $0 | 1,197,614 (Direct) |
View |
| 2021-06-21 Conversion |
2021-06-23 4:30 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Beam Therapeutics Inc. 10% Owner |
2,779,256 | $0 | 546,970 (Direct) |
View |
| 2021-06-21 Conversion |
2021-06-23 4:29 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | ARCH Venture Partners X LLC ARCH Venture Fund X L.P. ARCH Venture Fund X Overage L.P. ARCH Venture Partners X L.P. ARCH Venture Partners X Overage L.P. CRANDELL KEITH NELSEN ROBERT Burow Kristina GILLIS STEVEN 10% Owner |
25,739,146 | $0 | 1,254,405 (Indirect) |
View |
| 2021-06-21 Conversion |
2021-06-23 4:16 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Redmile Group LLC Green Jeremy 10% Owner |
9,095,362 | $0 | 1,936,530 (Indirect) |
View |
| 2021-06-21 Conversion |
2021-06-23 4:02 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Cormorant Asset Management LP Chen Bihua Cormorant Global Healthcare Master Fund LP Cormorant Private Healthcare Fund III LP Former 10% Owner |
709,224 | $0 | 984,224 (Indirect) |
View |
| 2021-06-21 Conversion |
2021-06-23 11:36 am |
N/A N/A |
Verve Therapeutics Inc. | VERV | FMR LLC See Remark 1 |
10,642,124 | $0 | 1,037,294 (Indirect) |
View |
| 2021-06-21 Conversion |
2021-06-22 5:21 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Logos Global Management LP 10% Owner |
4,547,681 | $0 | 813,265 (Indirect) |
View |
| 2021-06-21 Conversion |
2021-06-22 5:20 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Rock Springs Capital Management LP Rock Springs Capital Master Fund LP Rock Springs Capital LLC 10% Owner |
7,276,290 | $0 | 152,926 (Indirect) |
View |
| 2021-06-21 Conversion |
2021-06-22 5:20 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | GV 2017 GP L.L.C. GV 2017 GP L.P. GV 2017 L.P. 10% Owner |
64,849,333 | $0 | 6,320,905 (Indirect) |
View |
| 2021-06-21 Conversion |
2021-06-22 5:18 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | GV 2019 GP L.L.C. GV 2019 GP L.P. GV 2019 L.P. 10% Owner |
45,885,717 | $0 | 4,472,509 (Indirect) |
View |
| 2021-06-21 Conversion |
2021-06-22 5:17 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Novo Holdings A/S 10% Owner |
443,265 | $0 | 793,265 (Direct) |
View |
| 2021-06-21 Conversion |
2021-06-22 5:17 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Yeshwant Krishna Director 10% Owner |
110,735,050 | $0 | 4,472,509 (Indirect) |
View |
| 2021-06-21 Conversion |
2021-06-22 5:14 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% Owner |
25,603,317 | $0 | 2,495,571 (Direct) |
View |
| 2021-06-21 Conversion |
2021-06-22 5:12 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Casdin Private Growth Equity Fund L.P. 10% Owner |
6,366,754 | $0 | 620,571 (Direct) |
View |